Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

Expert Review of Vaccines

Volumn 2, Issue 2, 2003, Pages 285-293

  Peppoloni, Samuele ^b   Ruggiero, Paolo ^c   Contorni, Mario ^a   Morandi, Maurizio ^a   Pizza, Mariagrazia ^c   Rappuoli, Rino ^c   Podda, Audino ^a   Del Giudice, Giuseppe ^a  

^a CHIRON VACCINES   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c NONE

Author keywords

Adjuvants; CT; LT; Mucosal; Safety; Vaccines

Indexed keywords

BIOMATERIAL; BIOPOLYMER; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; ESCHERICHIA COLI ENTEROTOXIN; HELICOBACTER PYLORI VACCINE; HYALURONIC ACID; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; MICROSPHERE; MUTANT PROTEIN; PNEUMOCOCCUS VACCINE; PROTEIN LTH44A; PROTEIN LTK63; PROTEIN LTK72; PROTEIN LTR192G; PROTEIN SAG1; PROTEIN SUBUNIT; SHIGELLA VACCINE; TETANUS TOXOID; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ADHESION; AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; BACTERIAL MUTATION; BACTERIUM MUTANT; BELL PALSY; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; EDEMA; ENZYME ACTIVITY; EPITHELIUM HYPERPLASIA; ESCHERICHIA COLI; EXPERIMENTAL MODEL; FATIGUE; GOOD LABORATORY PRACTICE; GOOD MANUFACTURING PRACTICE; GRAM NEGATIVE INFECTION; HEADACHE; HEAT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; INFLAMMATION; INFLUENZA; MENINGITIS; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; NOSE CAVITY; OLFACTORY BULB; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHINORRHEA; SHIGELLA FLEXNERI; SIDE EFFECT; SITE DIRECTED MUTAGENESIS; SNEEZING; STREPTOCOCCUS INFECTION; TH1 CELL; TH2 CELL; TOXICITY; TRACHEA; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HUMANS; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; MUTATION; SAFETY; VACCINES;

EID: 0037992894     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.2.285     Document Type: Review

References (47)

1. Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20, 493-500 (1999).
2. Braun MC, He J, Wu CY, Kelsall BL. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression. J. Exp. Med. 189, 541-552 (1999).
3. Takahashi I, Marinaro M, Kimono H et al. Mechanisms of mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173, 627-635 (1996).
4. Yamamoto M, Kiyono H, Kweon MN et al. Enterotoxin adjuvants have direct effects on T-cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses. J. Infect. Dis. 182, 180-190 (2000).
5. Bowman CC, Clements JD. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heatlabile enterotoxin hybrids. Infect. Immun. 69, 1528-1535 (2001).
6. Wilson AD, Robinson A, Irons L, Stokes CR. Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigens. Vaccine 11, 113-118 (1993).
7. Burnette WN, Mar VL, Platler BW et al. Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity. Infect. Immun. 59, 4266-4270 (1991).
8. Jobling MG, Holmes RK. Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis. Mol. Microbiol. 5, 1755-1767 (1991).
9. Domenighini M, Magagnoli C, Pizza M, Rappuoli R. Common features of the NAD-binding and catalytic site of ADP-ribosylating toxins. Mol. Microbiol. 14, 41-50 (1994).
10. Dickinson DL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63, 1617-1623 (1995).
11. Giannelli V, Fontana MR, Giuliani MM, Guancgai D, Rappuoli R, Pizza M. Protease susceptibility and toxicity of heat-labile entetotoxins with a mutation in the active site or in the protease-sensitive loop. Infect. Immun. 65, 331-334 (1997).
12. Douce G, Turcotte C, Cropley I et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl Acad Sci. USA 92, 1644-1648 (1995).
13. Giuliani MM, Del Giudice G, Giannelli V et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187, 1123-1132 (1998).
14. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22, 2277-2281 (1992).
15. Pizza M, Domenighini M, Hol W et al. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 14, 51-60 (1994).
16. Pizza M, Fontana MR, Giuliani MM et al. A genetically detoxified derivative of heat-labile E. coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 180, 2147-2153 (1994).
17. de Haan L, Verweij WR, Feil IK et al. Mutants of Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect. Immun. 64, 5413-5416 (1996).
18. Douce G, Giuliani MM, Giannelli V, Pizza M, Rappuoli R, Dougan G. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16, 1065-1073 (1998).
19. Kato M, Imamura S, Kawase H, Miyama A, Tsuji T. Histidine-44 of the A subunit of Escherichia coli enterotoxin is involved in its enzymatic and biological activities. FEMS Microbiol. Lett. 152, 219-225 (1997).
20. Douce G, Giannelli V, Pizza M et al. Genetically detoxified mutants of heatlabile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun. 67, 4400-4406 (1999).
21. Ryan EJ, McNeela E, Murphy GA et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67, 6270-6280 (1999).
22. + cells.
23. Marinaro M, Staats HF, Hiroi T et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T-helper 2 (Th2) cells and IL-4. J. Immunol. 155, 4621-4629 (1995).
24. Ryan EJ, McNeela E, Pizza M, Rappuoli R, O'Neil L, Mills KH. Modulation of innate and acquired immune response by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J. Immunol 165, 5750-5759 (2000). Functional T-cell subset activation by LT muatants
25. Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Ann. Rev. Immunol. 19, 523-563 (2001).
26. Koprowski II H, Levine MM, Anderson RJ, Losonsky G, Pizza M, Barry EM. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect. Immun. 68, 4884-4892 (2000).
27. Scharton-Kersten T, Yu JM, Vassell R, O'Hagan D, Alving CR, Glenn GM. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits and unrelated adjuvants. Infect. Immun. 68, 5306-5313 (2000).
28. Ugozzoli M, Santos G, Donnelly J, O'Hagan DT. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. J. Infect. Dis. 183, 351-354 (2001).
29. Yuan L, Geyer A, Hodgins DC et al. Intranasal administration of 2/6-rotaviruslike particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J. Virol. 74, 8843-8853 (2000).
30. Greer CE, Petracca R, Buonamassa DT et al. The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus Type 6b (HPV-6b) virus-like particles. Vaccine 19, 1008-1012 (2000).
31. + cells.
32. Barackman JD, Ott G, O'Hagan DT. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and senun immunity, which is stronger than that with traditional intramuscular immunization. Infect. Immun. 67, 4276-4279 (1999).
33. Hagiwar Y, Tsuji T, Iwasaki T et al. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine. Vaccine 19, 2071-2079 (2001).
34. Jakobsen H, Bjarnarson S, Del Giudice G, Moreau M, Siegrist CA, Jonsdottir I. Intranasal immunization with pneumococcal conjugate vaccines with LTK63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect. Immun. 70, 1443-1452 (2002). Adjuvanticity of LTK63 in neonates.
35. Bonenfant C, Bimier-Poisson I, Velge-Roussel F et al. Intranasal immunization with SAG I and nontoxic mutant heatlabile enterotoxins protects mice against Toxoplasma gondii. Infect. Immun. 69, 1605-1612 (2001).
36. Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J. Control. Release 70, 267-276 (2001).
37. Baudner BC, Balland O, Giuliani MM et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun. 70, 4785-4790 (2002). Additive effect of LTK63 and bioadhesive material after intranasal immunization.
38. Ricciardi-Castagnoli P, Granucci F. Interpretation of the complexity of innate immune responses by functional genomics. Nat. Rev. Immunol. 2, 881-889 (2002).
39. Pizza M, Giuliani MM, Fontana MT et al. Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 21, 2534-2541 (2001).
40. Glück U, Gebbers JO, Glück R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73, 7780-7786 (1999).
41. Glück R, Mischler R, Durrer P et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181, 1129-1132 (2000).
42. Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pyloriinfected adults. Gastroenterology 116, 804-812 (1999).
43. Van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol. 165, 4778-4782 (2000).
44. Cheng E, Cardenas-Freytag L, Clements JD. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18, 38-49 (1999).
45. Bisteau M, Abarca J, Bourguignon P, Hermand P, Francotte M. Intranasal administration of enterotoxins induces reactogenicity in the brain of different mice strains. In: Euroconference Workshop, Novel Strategies of Mucosal Immunization through Exploitation of Mechanisms of Innate Immunity in Pathogen-Host Interaction, Siena, Italy 6-10, 80 (2002).
46. Simecka JW, Jackson RJ, Kiyono H, McGhee JR. Mucosally induced immunoglobulin E - associated inflammation in the respiratory tract. Infect. Immun. 68, 672-679 (2000)
47. Kodoff K, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker R. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69, 3581-3590 (2001).